Does the media favor BBIO or EWTX?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat BridgeBio Pharma's score of 1.17 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ASND or EWTX?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Ascendis Pharma A/S's score of 1.13 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor EWTX or EXEL?

In the previous week, Exelixis had 23 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 33 mentions for Exelixis and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Exelixis' score of 1.14 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Exelixis 22 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMRN or EWTX?

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat BioMarin Pharmaceutical's score of 1.59 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 17 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to HALO or EWTX?

In the previous week, Halozyme Therapeutics had 20 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 30 mentions for Halozyme Therapeutics and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Halozyme Therapeutics' score of 1.37 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 25 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Edgewise Therapeutics (EWTX) Competitors

$42.76 -1.43 (-3.24%)

As of 08/28/2026 04:00 PM Eastern

Compare

EWTX vs. BBIO, ASND, EXEL, BMRN, and HALO

Should you buy Edgewise Therapeutics stock or one of its competitors? Edgewise Therapeutics's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Edgewise Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

BridgeBio Pharma has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Edgewise Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	21.00	-$724.93M	-$3.57	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

99.8% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, BridgeBio Pharma had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat BridgeBio Pharma's score of 1.17 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Edgewise Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

BridgeBio Pharma currently has a consensus target price of $100.79, indicating a potential upside of 31.58%. Edgewise Therapeutics has a consensus target price of $50.33, indicating a potential upside of 17.71%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

BridgeBio Pharma beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Ascendis Pharma A/S currently has a consensus price target of $302.68, indicating a potential upside of 22.09%. Edgewise Therapeutics has a consensus price target of $50.33, indicating a potential upside of 17.71%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Edgewise Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.99	-$258M	$12.89	19.23
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Ascendis Pharma A/S's score of 1.13 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to Edgewise Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Summary

Ascendis Pharma A/S beats Edgewise Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Exelixis?

Edgewise Therapeutics (NASDAQ:EWTX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Edgewise Therapeutics currently has a consensus price target of $50.33, suggesting a potential upside of 17.71%. Exelixis has a consensus price target of $50.07, suggesting a potential downside of 8.05%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Exelixis has a net margin of 35.33% compared to Edgewise Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Exelixis	35.33%	42.17%	31.76%

Exelixis has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Exelixis	$2.44B	5.54	$782.57M	$3.18	17.12

In the previous week, Exelixis had 23 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 33 mentions for Exelixis and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Exelixis' score of 1.14 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Exelixis	22 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Exelixis beats Edgewise Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Edgewise Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

BioMarin Pharmaceutical currently has a consensus price target of $88.79, suggesting a potential upside of 37.30%. Edgewise Therapeutics has a consensus price target of $50.33, suggesting a potential upside of 17.71%. Given BioMarin Pharmaceutical's higher possible upside, research analysts clearly believe BioMarin Pharmaceutical is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat BioMarin Pharmaceutical's score of 1.59 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	17 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.41B	3.67	$348.90M	$0.37	174.78
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Summary

BioMarin Pharmaceutical beats Edgewise Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Halozyme Therapeutics has a net margin of 24.86% compared to Edgewise Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Halozyme Therapeutics presently has a consensus price target of $91.20, suggesting a potential downside of 13.43%. Edgewise Therapeutics has a consensus price target of $50.33, suggesting a potential upside of 17.71%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Halozyme Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

In the previous week, Halozyme Therapeutics had 20 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 30 mentions for Halozyme Therapeutics and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Halozyme Therapeutics' score of 1.37 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	25 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.56	$316.89M	$3.35	31.45
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Summary

Halozyme Therapeutics beats Edgewise Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EWTX vs. The Competition

Export

Metric	Edgewise Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.64B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-23.11	11.62	273.16	25.45
Price / Sales	N/A	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	10.35	16.53	12.98	6.14
Net Income	-$167.79M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-3.21%	-0.31%	0.13%	-0.80%
1 Month Performance	3.99%	9.80%	7.08%	4.13%
1 Year Performance	197.98%	55.66%	24.67%	15.17%

Edgewise Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EWTX Edgewise Therapeutics	3.3248 of 5 stars	$42.76 -3.2%	$50.33 +17.7%	+198.0%	$4.64B	N/A	N/A	60	News Coverage Positive News
BBIO BridgeBio Pharma	3.4598 of 5 stars	$80.40 -0.8%	$100.79 +25.4%	+48.0%	$15.85B	$502.08M	N/A	400	Positive News
ASND Ascendis Pharma A/S	4.7031 of 5 stars	$252.99 +0.4%	$300.33 +18.7%	+27.6%	$15.72B	$814.57M	19.63	1,189	Analyst Forecast Analyst Revision
EXEL Exelixis	3.1006 of 5 stars	$56.72 +4.0%	$50.07 -11.7%	+45.5%	$13.52B	$2.32B	17.84	1,077	Trending News Options Volume Analyst Revision
BMRN BioMarin Pharmaceutical	4.9111 of 5 stars	$66.12 +1.6%	$88.83 +34.3%	+11.0%	$12.60B	$3.22B	178.70	3,221	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EWTX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. BBIO, ASND, EXEL, BMRN, and HALO

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Edgewise Therapeutics compare to Exelixis?

Summary

How does Edgewise Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Edgewise Therapeutics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. BBIO, ASND, EXEL, BMRN, and HALO

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or EWTX?

Which has preferable valuation and earnings, BBIO or EWTX?

Do institutionals & insiders have more ownership in BBIO or EWTX?

Does the media favor BBIO or EWTX?

Is BBIO or EWTX more profitable?

Do analysts prefer BBIO or EWTX?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Do analysts rate ASND or EWTX?

Which has more volatility & risk, ASND or EWTX?

Which has better valuation and earnings, ASND or EWTX?

Does the media favor ASND or EWTX?

Is ASND or EWTX more profitable?

Summary

How does Edgewise Therapeutics compare to Exelixis?

Do analysts prefer EWTX or EXEL?

Is EWTX or EXEL more profitable?

Which has higher valuation and earnings, EWTX or EXEL?

Does the media favor EWTX or EXEL?

Which has more volatility and risk, EWTX or EXEL?

Do insiders and institutionals hold more shares of EWTX or EXEL?

Summary

How does Edgewise Therapeutics compare to BioMarin Pharmaceutical?

Do institutionals and insiders believe in BMRN or EWTX?

Is BMRN or EWTX more profitable?

Do analysts prefer BMRN or EWTX?

Does the media prefer BMRN or EWTX?

Which has more volatility & risk, BMRN or EWTX?

Which has higher earnings and valuation, BMRN or EWTX?

Summary

How does Edgewise Therapeutics compare to Halozyme Therapeutics?

Is HALO or EWTX more profitable?

Do analysts recommend HALO or EWTX?

Which has more risk and volatility, HALO or EWTX?

Does the media refer more to HALO or EWTX?

Do institutionals & insiders hold more shares of HALO or EWTX?

Which has stronger valuation and earnings, HALO or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools